Anti-hla-dr antibody
CA 2463634 A1 · Owner: Tawara, Tomonori · Inventors: Tawara, Tomonori; Kataoka, Shiro
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
It is intended to provide an anti-HLA-DR monoclonal antibody. Namely an , antibody binding to HLA-DR having characteristics of (a) showing a lifeprolonging effect on a nonhuman animal carrying cancer cells with HLA-DR expression and (b) having a lower immune reaction inhibitory activity than L243 or a functional fragment thereof; or an antibody binding to HLA-DR showing an immunosuppressive activity comparable to or higher than mouse anti- HLA-DR monoclonal antibody L243 (ATCC HB-55) or a functional fragment thereof.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 15, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 15, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 15, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.